BioPharm Asia Announces Hospital Management Contract
December 19 2011 - 9:00AM
Marketwired
BioPharm Asia (PINKSHEETS: BFAR) and Elite Capital Group announced
today the signing of a consulting agreement for the development of
a 1,000-bed Fangzhuang Hospital and Training Center to be located
in Fangzhuang, Beijing. BioPharm Asia will serve as master
consultant for the project which is scheduled to begin construction
in 2012.
Xiayang Hu, CEO of BioPharm Asia, said, "We are delighted to
confirm Elite Capital Group's contract in which our Hospital
Management Division will provide key development services as well
as assist in the operations of the facility. We are confident that
we have the range of skills and services to help Elite Capital
Management create new models of healthcare and flexible therapeutic
environments."
Andrew Lee, Partner & Managing Director of Elite Capital
Group, said, "Substandard healthcare is changing in China,
especially the rapid economic progress has improved the financial
well being of china's growing middle class. The demands of
courteous healthcare professionals in the residential area have
risen sharply. Our focus is to pursue this major phenomenon in the
Chinese healthcare marketplace and with the help of BioPharm Asia's
hospital management expertise to develop a chain of efficient,
clean, well-maintained hospitals."
About BioPharm Asia,
Inc.
BioPharm Asia, Inc. is engaged in the retail sale of medical
products in China, complemented by vertically integrated supporting
functions that include the cultivation of Chinese herbal medicines,
pharmaceutical production and wholesale medicine distribution. For
more information, please visit http://www.biopharmasiainc.com.
For more information: BioPharm Asia, Inc. Gloria Fang
(86) 135-3407-3970 Email Contact